• Explore /
  • Poster
  • / An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).

An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).

Abstract Poster

Authors

Luciano J. Costa

Luciano J. Costa

University of Alabama at Birmingham, Birmingham, AL

Luciano J. Costa , Thomas William LeBlanc , Hans Tesch , Pieter Sonneveld , Ryan Kyle , Liliya Sinyavskaya , Patrick Hlavacek , Aster Meche , Jinma Ren , Alex Schepart , Didem Aydin , Marco DiBonaventura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6618)

DOI

10.1200/JCO.2023.41.16_suppl.6618

Abstract #

6618

Poster Bd #

110

Abstract Disclosures

Similar Posters

First Author: Xavier Leleu

First Author: Dagmar Hess

First Author: Eiji Shinozaki

First Author: Andrzej J. Jakubowiak